Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group

Carroll, 1997, CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing Bcr-Abl, Tel-Abl, and Tel-PDGFR fusion proteins, Blood, 90, 4947, 10.1182/blood.V90.12.4947 Buchdunger, 2000, Abl protein-tyrosine kinase inhibitor STI 571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors, J Pharmacol Exp Ther, 295, 139 Van Oosterom, 2001, Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study, Lancet, 358, 1421, 10.1016/S0140-6736(01)06535-7 Faderl, 1999, The biology of chronic myeloid leukemia, N Engl J Med, 341, 164, 10.1056/NEJM199907153410306 Druker, 2001, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N Engl J Med, 344, 1031, 10.1056/NEJM200104053441401 Druker, 2001, Activity of a specific inhibitor of teh Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome, N Engl J Med, 344, 1038, 10.1056/NEJM200104053441402 Heinrich, 2000, Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor, Blood, 96, 925, 10.1182/blood.V96.3.925 Tuveson, 2001, STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications, Oncogene, 20, 5054, 10.1038/sj.onc.1204704 Berman, 2001, Gastrointestinal stromal tumor workshop, 32, 578 Lasota, 1999, Mutations inexon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas, Am J Pathol, 154, 53, 10.1016/S0002-9440(10)65250-9 Lux, 2000, KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors, Am J Pathol, 156, 791, 10.1016/S0002-9440(10)64946-2 Rubin, 2001, KIT activation is a ubiquitous feature of gastrointestinal stromal tumors, Cancer Res, 61, 8118 1998, Cancer Therapy Evaluation Program Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Young, 1999, Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations, Eur J Cancer, 35, 1773, 10.1016/S0959-8049(99)00229-4 Verweij, 2001, STI571: a magic bullet?, Eur J Cancer, 37, 1816, 10.1016/S0959-8049(01)00237-4